HB/APAP

DRUG6 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Acute Pain

Phase 2

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

CompletedNCT03206749

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2017-06-29End: 2017-12-08Updated: 2021-02-03

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

CompletedNCT04977336

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2021-07-19End: 2022-03-04Updated: 2025-06-25

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

CompletedNCT05034952

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2021-08-30End: 2021-12-21Updated: 2024-12-27

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

CompletedNCT06619847

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2024-10-29End: 2025-05-27Updated: 2025-06-26

Phase 3

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

CompletedNCT05553366

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2022-10-03End: 2023-12-15Updated: 2025-08-01

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

CompletedNCT05558410

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2022-10-10End: 2023-09-11Updated: 2025-07-01

Related Papers

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

Anesthesiology2025-03-2128 citations

Selective Inhibition of Na <sub>V</sub> 1.8 with VX-548 for Acute Pain

New England Journal of Medicine2023-08-02216 citations